John Overdeck’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

John Overdeck’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-302,015	Closed	-$268K	–	3338
2022 Q4	$268K	Hold	302,015	–	–	﹤0.01%	2285
2022 Q3	$474K	Hold	302,015	–	–	﹤0.01%	1803
2022 Q2	$607K	Sell	302,015 -786,685	-72%	-$1.36M	﹤0.01%	1745
2022 Q1	$2.54M	Buy	+1,088,700	New	+$3.4M	0.01%	1232
2015 Q2	–	Sell	-73,035	Closed	-$844K	–	3179
2015 Q1	$844K	Buy	73,035 +41,158	+129%	+$476K	﹤0.01%	1682
2014 Q4	$321K	Buy	+31,877	New	+$161K	﹤0.01%	1899

Other funds holding SRNE

Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

OFA

Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return

CGA

Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return

LCM

Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return

STB

S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return

GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return

HFRG

Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return

VFA

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return

GBWM

Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

John Overdeck's SRNE Position: Q1 2023 in Review

John Overdeck sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 302,015 shares — an estimated $268K sold.

John Overdeck first reported a position in SRNE in Q4 2014 and held it in 6 quarters. The position peaked at $2.54M in Q1 2022. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

John Overdeck reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
John Overdeck sold 302,015 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $268K.
John Overdeck first reported a position in Sorrento Therapeutics, Inc. in Q4 2014 and held it in 6 quarters.
John Overdeck's Sorrento Therapeutics, Inc. position peaked at $2.54M in Q1 2022.
34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Two Sigma Investments's 13F filing for Q1 2023, filed 15 May 2023.